Skip to main content
Quest Diagnostics

Simultaneous Quantification of Intact Proinsulin, Proinsulin Metabolic Intermediates, Insulin, C-Peptide, and C-Peptide Cleavage Variants by LC-MS

MSACLUS 2024

Mass Spectrometry a& Advances in the Clinical Lab

Monterey, CA, March 17-22, 2024

Oral presentation: Simultaneous Quantification of Intact Proinsulin, Proinsulin Metabolic Intermediates, Insulin, C-Peptide, and C-Peptide Cleavage Variants by LC-MS

Authors: Pearce RW, McPhaul MJ, Collier TS

Specialty: Cardiovascular disease, Cardiology, Endocrinology

Related content

On-Demand Webinar
Early Identification of Type 2 Diabetes Risk for the Primary Care Setting
Publication
Insulin Resistance Probability Score and Incident Cardiovascular Disease
Publication
Critical need to assess modified and un-modified peptides in C-peptide standard materials
Test FAQ
CardioIQ® Insulin Resistance Panel with Score
Publication
An Insulin Resistance Score Improved Diabetes Risk Assessment in the Malmö Prevention Project-A Longitudinal Population-Based Study of Older European

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.